MARCHF5 and lung carcinoma: Significantly, MARCH5 depletion both abrogated the decrease in MCL1 in response to erlotinib and substantially increased basal MCL1 in multiple prostate, breast, and lung cancer cell lines, indicating that MARCH5 makes a major contribution to regulating basal levels of MCL1.